Literature DB >> 19081762

siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli.

Richard Tritz1, Barbara M Mueller, Michelle J Hickey, Amy H Lin, German G Gomez, Philipp Hadwiger, Dinah W Y Sah, Leslie Muldoon, Edward A Neuwelt, Carol A Kruse.   

Abstract

The PATZ1 gene encodes a transcription factor that belongs to the BTB/POZ group of transcriptional regulators and has been implicated as a transcriptional repressor. We cloned cDNA from glioma cell lines and found they expressed transcript variant 2 of PATZ1. We designed a specific siRNA against PATZ1 and showed that this siRNA, but not a control randomized siRNA, reduced PATZ1 expression in glioma cells as determined by quantitative PCR. In a panel of human glioma cell lines incubated with proapoptotic FasL, those transfected with PATZ1 siRNA displayed reduced cell numbers by the MTT colorimetric assay, relative to those transfected with randomized siRNA. Further studies showed that in 10-08-MG, U-251MG, U-87MG, and T98G cells PATZ1 siRNA significantly increased apoptosis in response to incubation with soluble FasL, as shown by a morphologic acridine orange/ethidium bromide apoptotic assay. Using an apoptosis specific cDNA microarray we further demonstrated that down-regulation of PATZ1 by siRNA resulted in the upregulation of death receptor pro-apoptotic genes including caspase 8 and Death Receptor 5 (DR5) in U-373MG cells. Since DR5 is the receptor for TRAIL we tested whether PATZ1 downregulation also sensitized cells to TRAIL-induced apoptosis and found that PATZ1 siRNA, but not control siRNA, sensitized U-251MG and T98G glioma cells to TRAIL-induced apoptosis. Altogether, these data demonstrate a previously unknown role for the transcription factor PATZ1 in conferring resistance to apoptosis and indicate that modulation of PATZ1 expression may be a therapeutic strategy for gliomas.

Entities:  

Year:  2008        PMID: 19081762      PMCID: PMC2600477     

Source DB:  PubMed          Journal:  Cancer Ther


  26 in total

1.  A novel member of the BTB/POZ family, PATZ, associates with the RNF4 RING finger protein and acts as a transcriptional repressor.

Authors:  M Fedele; G Benvenuto; R Pero; B Majello; S Battista; F Lembo; E Vollono; P M Day; M Santoro; L Lania; C B Bruni; A Fusco; L Chiariotti
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

2.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

3.  FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.

Authors:  Erik D Foehr; Gustavo Lorente; Valerie Vincent; Karoly Nikolich; Roman Urfer
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

4.  Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation.

Authors:  Constantine S Mitsiades; Vassiliki Poulaki; Galinos Fanourakis; Elias Sozopoulos; Douglas McMillin; Zhaoqin Wen; Gerassimos Voutsinas; Sophia Tseleni-Balafouta; Nicholas Mitsiades
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

5.  The BTB domain, found primarily in zinc finger proteins, defines an evolutionarily conserved family that includes several developmentally regulated genes in Drosophila.

Authors:  S Zollman; D Godt; G G Privé; J L Couderc; F A Laski
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

6.  The POZ domain: a conserved protein-protein interaction motif.

Authors:  V J Bardwell; R Treisman
Journal:  Genes Dev       Date:  1994-07-15       Impact factor: 11.361

7.  Epigenetic changes in tumor Fas levels determine immune escape and response to therapy.

Authors:  Heather L Maecker; Zhong Yun; Holden T Maecker; Amato J Giaccia
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

8.  Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.

Authors:  Daniela Opel; Mike-Andrew Westhoff; Ariane Bender; Veit Braun; Klaus-Michael Debatin; Simone Fulda
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

9.  Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme.

Authors:  Markus Hutterer; Pjotr Knyazev; Ariane Abate; Markus Reschke; Hans Maier; Nadia Stefanova; Tatjana Knyazeva; Verena Barbieri; Markus Reindl; Armin Muigg; Herwig Kostron; Guenther Stockhammer; Axel Ullrich
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

10.  PATZ1 gene has a critical role in the spermatogenesis and testicular tumours.

Authors:  M Fedele; R Franco; G Salvatore; M P Paronetto; F Barbagallo; R Pero; L Chiariotti; C Sette; D Tramontano; G Chieffi; A Fusco; P Chieffi
Journal:  J Pathol       Date:  2008-05       Impact factor: 7.996

View more
  17 in total

1.  Interaction of the regulatory subunit of the cAMP-dependent protein kinase with PATZ1 (ZNF278).

Authors:  Weng-Lang Yang; Roald Ravatn; Kazuya Kudoh; Leah Alabanza; Khew-Voon Chin
Journal:  Biochem Biophys Res Commun       Date:  2009-12-22       Impact factor: 3.575

2.  POZ/BTB and AT-hook-containing zinc finger protein 1 (PATZ1) inhibits endothelial cell senescence through a p53 dependent pathway.

Authors:  J H Cho; M J Kim; K J Kim; J-R Kim
Journal:  Cell Death Differ       Date:  2011-11-04       Impact factor: 15.828

3.  POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.

Authors:  Raffaela Pero; Dario Palmieri; Tiziana Angrisano; Teresa Valentino; Antonella Federico; Renato Franco; Francesca Lembo; Andres J Klein-Szanto; Luigi Del Vecchio; Donatella Montanaro; Simona Keller; Claudio Arra; Vasiliki Papadopoulou; Simon D Wagner; Carlo M Croce; Alfredo Fusco; Lorenzo Chiariotti; Monica Fedele
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

4.  FAPP2 gene downregulation increases tumor cell sensitivity to Fas-induced apoptosis.

Authors:  Richard Tritz; Michelle J Hickey; Amy H Lin; Philipp Hadwiger; Dinah W Y Sah; Edward A Neuwelt; Barbara M Mueller; Carol A Kruse
Journal:  Biochem Biophys Res Commun       Date:  2009-03-31       Impact factor: 3.575

5.  PATZ1 Induces Apoptosis through PUMA in Glioblastoma.

Authors:  Xiang Tao; Ge Zhang; Junhui Liu; Baowei Ji; Haitao Xu; Zhibiao Chen
Journal:  J Oncol       Date:  2022-04-25       Impact factor: 4.501

6.  PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration.

Authors:  Gennaro Chiappetta; Teresa Valentino; Michela Vitiello; Rosa Pasquinelli; Mario Monaco; Giuseppe Palma; Romina Sepe; Antonio Luciano; Pierlorenzo Pallante; Dario Palmieri; Concetta Aiello; Domenica Rea; Simona Nunzia Losito; Claudio Arra; Alfredo Fusco; Monica Fedele
Journal:  Oncotarget       Date:  2015-03-10

7.  PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context.

Authors:  T Valentino; D Palmieri; M Vitiello; G M Pierantoni; A Fusco; M Fedele
Journal:  Cell Death Dis       Date:  2013-12-12       Impact factor: 8.469

8.  Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma.

Authors:  Yongqing Wang; Bashar Kahaleh
Journal:  J Cell Mol Med       Date:  2013-07-16       Impact factor: 5.310

9.  The dosage of Patz1 modulates reprogramming process.

Authors:  Hui Ma; Jin Rong Ow; Bobby Cheng Peow Tan; Ziyi Goh; Bo Feng; Yuin Han Loh; Monica Fedele; Hu Li; Qiang Wu
Journal:  Sci Rep       Date:  2014-12-17       Impact factor: 4.379

10.  PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells.

Authors:  Michela Vitiello; Teresa Valentino; Marta De Menna; Elvira Crescenzi; Paola Francesca; Domenica Rea; Claudio Arra; Alfredo Fusco; Gabriella De Vita; Laura Cerchia; Monica Fedele
Journal:  Sci Rep       Date:  2016-04-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.